Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
Justin Grenet(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Gail J. Roboz(Cornell University), Maximilian Stahl(Harvard University), Xiaoyue Ma(Xi'an Jiaotong University), Julian A. Waksal(Memorial Sloan Kettering Cancer Center), Paul J. Christos(Cornell University), Akriti Jain(Cleveland Clinic), Kendra Sweet(Moffitt Cancer Center), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Brian Ball(City Of Hope National Medical Center), Shira Dinner(Dana-Farber Cancer Institute), Christopher Famulare(Memorial Sloan Kettering Cancer Center), Justin D. Kaner(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Zoe McKinnell(Memorial Sloan Kettering Cancer Center), Sangmin Lee(Ulsan College), Yazan Numan(Northwestern University), Michael Samuel(NewYork–Presbyterian Hospital), Madelyn Burkart(Atrium Health Wake Forest Baptist)
Cited by 20
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k